Equity fund forecasts weight-loss drug market frenzy far from finish line
Capital Group fund says it sees long-term opportunity in the development of drugs like Novo’s Ozempic
A global equity firm well-versed in pharmaceutical investing is betting the ongoing frenzy in weight-loss drug stock has further to run.
Novo Nordisk and Eli Lilly are among top holdings in the A$1.3 billion (€786.9 million) Capital Group New Perspective Fund, which is beating 94 per cent of peers this year, according to data compiled by Bloomberg.
The long-standing fund, which first invested in the two companies long before recent fervour for obesity treatments, claims ...